ETI-MAK-4

Glavna informacija

  • Trgovački naziv:
  • ETI-MAK-4, HBsAgConf.Test, ET-AB-AUK-3, ETI-AB-COREK PLUS, ETI-CORE-IGMK PLUS, ETI-AB-EBK PLUS, ETI-EBK PLUS, ETI-AB-HCVK4(SO-NO
  • Koristi za:
  • Ljudi
  • Vrsta lijekova:
  • Medicinski uređaj
  • Proizveden od:
  • DiaSorin S.p.A., Via Crescentino, snc, Saluggia, Italija

Dokument

  • za javnost:
  • Informativni letak za ovaj proizvod trenutno nije dostupan, možete poslati zahtjev na našu službu za korisnike, a mi ćemo vas obavijestiti čim smo u mogućnosti da ga dobiju.


    Zatražite informativni letak za javnost.

Lokalizacija

  • Na raspolaganju u:
  • ETI-MAK-4, HBsAgConf.Test, ET-AB-AUK-3, ETI-AB-COREK PLUS, ETI-CORE-IGMK PLUS, ETI-AB-EBK PLUS, ETI-EBK PLUS, ETI-AB-HCVK4(SO-NO
    Hrvatska
  • Jezik:
  • hrvatski

Terapeutski informacija

  • Terapijska grupa:
  • potvrda prisutnosti virusa HBsAG u serumu

Druge informacije

Status

  • Izvor:
  • HALMED Agencija za lijekove i medicinske proizvode - Agency for medicinal products and medical devices of Croatia
  • Datum autorizacije:
  • 15-11-2005
  • Zadnje ažuriranje:
  • 05-06-2018
  • Informativni letak za ovaj proizvod trenutno nije dostupan, možete poslati zahtjev na našu službu za korisnike, a mi ćemo vas obavijestiti čim smo u mogućnosti da ga dobiju.

    Zatražite informativni letak za javnost.

20-3-2019


Management Board meeting: 21 March 2019, European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2019 to 21/03/2019

Management Board meeting: 21 March 2019, European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2019 to 21/03/2019

Management Board meeting: 21 March 2019, European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2019 to 21/03/2019

Europe - EMA - European Medicines Agency

20-3-2019


Agenda for the 103rd meeting of the Management Board

Agenda for the 103rd meeting of the Management Board

Agenda for the 103rd meeting of the Management Board

Europe - EMA - European Medicines Agency

20-3-2019


Agenda - COMP agenda of the 19-21 March 2019 meeting

Agenda - COMP agenda of the 19-21 March 2019 meeting

Agenda - COMP agenda of the 19-21 March 2019 meeting

Europe - EMA - European Medicines Agency

19-3-2019

FDA takes action against marketer of unapproved products claiming to treat addiction, chronic pain and other serious conditions

FDA takes action against marketer of unapproved products claiming to treat addiction, chronic pain and other serious conditions

FDA warned Nutra Pharma for illegally marketing unapproved products with claims about their ability to treat addiction, pain and other serious conditions.

FDA - U.S. Food and Drug Administration

14-3-2019

FDA allows marketing of new device to help treat carbon monoxide poisoning

FDA allows marketing of new device to help treat carbon monoxide poisoning

FDA allows marketing of a new device, ClearMate, intended to be used with patients suffering from carbon monoxide poisoning. This is the first carbon monoxide poisoning device authorized for marketing by the FDA for use in an emergency room setting.

FDA - U.S. Food and Drug Administration

12-3-2019


Agenda - PRAC draft agenda of meeting 12-15 March 2019

Agenda - PRAC draft agenda of meeting 12-15 March 2019

Agenda - PRAC draft agenda of meeting 12-15 March 2019

Europe - EMA - European Medicines Agency

12-3-2019


Agenda - CAT agenda of the 20-22 February 2019 meeting

Agenda - CAT agenda of the 20-22 February 2019 meeting

Agenda - CAT agenda of the 20-22 February 2019 meeting

Europe - EMA - European Medicines Agency

6-3-2019

Homeopathic remedies are not a substitute for vaccines

Homeopathic remedies are not a substitute for vaccines

OTTAWA – Health Canada is concerned about false claims being made in some marketing of homeopathic remedies, known as nosodes, stating that the product can prevent infectious diseases. Nosodes are not, and never have been, approved by Health Canada to be vaccine alternatives. There is no evidence supporting their effectiveness in preventing or treating infectious diseases. No homeopathic products should be promoted as an alternative to vaccines because there are no substitutes for vaccines.

Health Canada

25-2-2019

Golean Detox USA Issues Voluntary Nationwide Recall of Golean DETOX Capsules Due to Presence of Undeclared Sibutramine and Phenolphthalein

Golean Detox USA Issues Voluntary Nationwide Recall of Golean DETOX Capsules Due to Presence of Undeclared Sibutramine and Phenolphthalein

Golean Detox USA, Charlotte, NC is voluntarily recalling all lots within expiry of Golean DETOX capsules to the consumer level. FDA analysis has found Golean DETOX capsules to be tainted with undeclared sibutramine and phenolphthalein. Sibutramine is an appetite suppressant that was withdrawn from the U.S. market due to safety concerns. Phenolphthalein was once an ingredient used in over-the-counter laxatives, but because of concerns of carcinogenicity is not currently approved for marketing in the Unite...

FDA - U.S. Food and Drug Administration

25-2-2019

FDA issues warning letter to clinic illegally marketing unapproved thermography device, warns consumers to avoid using thermography devices to detect breast cancer

FDA issues warning letter to clinic illegally marketing unapproved thermography device, warns consumers to avoid using thermography devices to detect breast cancer

FDA issues warning letter to clinic illegally marketing unapproved thermography device, warns consumers to avoid using thermography devices to detect breast cancer

FDA - U.S. Food and Drug Administration

25-2-2019

FDA-Approved Devices That Keep the Heart Beating

FDA-Approved Devices That Keep the Heart Beating

Cardiovascular devices (or 'heart' devices) such as pacemakers and defibrillators have extended and improved the lives of millions of people worldwide. Learn how the FDA regulates these devices, when to seek medical attention for potential heart issues, and how to report problems.

FDA - U.S. Food and Drug Administration

21-2-2019

Annual report of the EFSA Scientific Network for Risk Assessment of GMOs for 2018

Annual report of the EFSA Scientific Network for Risk Assessment of GMOs for 2018

Published on: Wed, 20 Feb 2019 The EFSA Scientific Network for Risk Assessment of GMOs (the GMO Network) was established in accordance with EFSA's strategy for cooperation and networking with Member States. The goals of the GMO Network are to improve dialogue among members, build mutual understanding of risk assessment principles, enhance knowledge and confidence in the scientific assessment carried out in the EU, and increase the transparency of the process among Member States and EFSA. The annual repo...

Europe - EFSA - European Food Safety Authority EFSA Journal

15-2-2019

Food allergies: improve information to prevent risks

Food allergies: improve information to prevent risks

With the constant changes in eating habits and the marketing of novel foods, food allergies continue to be a public health concern.  As a result of its expert assessment work, ANSES found that there was a lack of data on the prevalence of food allergies in France. The Agency therefore delivers a series of recommendations to ensure better monitoring of food allergies, and recommends providing better information to doctors as well as to consumers subject to food allergies.

France - Agence Nationale du Médicament Vétérinaire

14-2-2019

FDA issues warning letter to doctor for illegally marketing unapproved device with claims to prevent and treat tightening of scar tissue around breast implants

FDA issues warning letter to doctor for illegally marketing unapproved device with claims to prevent and treat tightening of scar tissue around breast implants

FDA issues warning letter to doctor for illegally marketing unapproved device with claims to prevent and treat tightening of scar tissue around breast implants

FDA - U.S. Food and Drug Administration

11-2-2019


Agenda - PRAC draft agenda of meeting 11-14 February 2019

Agenda - PRAC draft agenda of meeting 11-14 February 2019

Agenda - PRAC draft agenda of meeting 11-14 February 2019

Europe - EMA - European Medicines Agency

27-3-2019

Pemetrexed Accord (Accord Healthcare S.L.U.)

Pemetrexed Accord (Accord Healthcare S.L.U.)

Pemetrexed Accord (Active substance: pemetrexed) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1669 of Wed, 27 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4072/T/06

Europe -DG Health and Food Safety

19-3-2019

Loxicom (Norbrook Laboratories (Ireland) Limited)

Loxicom (Norbrook Laboratories (Ireland) Limited)

Loxicom (Active substance: Meloxicam) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2179 of Tue, 19 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/141/T/32

Europe -DG Health and Food Safety

15-3-2019


Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019

Europe - EMA - European Medicines Agency

15-3-2019

Intrarosa (Endoceutics S.A.)

Intrarosa (Endoceutics S.A.)

Intrarosa (Active substance: prasterone) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2063 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/004138/T/0005

Europe -DG Health and Food Safety

15-3-2019

Zoledronic acid Accord (Accord Healthcare S.L.U.)

Zoledronic acid Accord (Accord Healthcare S.L.U.)

Zoledronic acid Accord (Active substance: zoledronic acid) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2071 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/002667/T/0007

Europe -DG Health and Food Safety

14-3-2019

Aivlosin (ECO Animal Health Europe Limited)

Aivlosin (ECO Animal Health Europe Limited)

Aivlosin (Active substance: Tylvalosin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2091 of Thu, 14 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/83/T/77

Europe -DG Health and Food Safety

14-3-2019

Reconcile (Pegasus Laboratories Ireland Limited)

Reconcile (Pegasus Laboratories Ireland Limited)

Reconcile (Active substance: Fluoxetine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2089 of Thu, 14 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/133/T/31

Europe -DG Health and Food Safety

13-3-2019

Luminity (Lantheus EU Limited)

Luminity (Lantheus EU Limited)

Luminity (Active substance: perflutren) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2049 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/654/T/27

Europe -DG Health and Food Safety

13-3-2019

Qarziba (EUSA Pharma (Netherlands) B.V.)

Qarziba (EUSA Pharma (Netherlands) B.V.)

Qarziba (Active substance: dinutuximab beta) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2061 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/3918/T/10

Europe -DG Health and Food Safety

13-3-2019

Cresemba (Basilea Pharmaceutica Deutschland GmbH)

Cresemba (Basilea Pharmaceutica Deutschland GmbH)

Cresemba (Active substance: isavuconazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2069 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2734/T/20

Europe -DG Health and Food Safety

13-3-2019

Stayveer (Janssen Pharmaceutica N.V.)

Stayveer (Janssen Pharmaceutica N.V.)

Stayveer (Active substance: bosentan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2065 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2644/T/25

Europe -DG Health and Food Safety

13-3-2019

Varuby (TESARO Bio Netherlands B.V.)

Varuby (TESARO Bio Netherlands B.V.)

Varuby (Active substance: rolapitant) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2068 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4196/T/15

Europe -DG Health and Food Safety

13-3-2019

Senshio (Shionogi B.V.)

Senshio (Shionogi B.V.)

Senshio (Active substance: ospemifene) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2066 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2780/T/26

Europe -DG Health and Food Safety

13-3-2019

Slenyto (RAD Neurim Pharmaceuticals EEC SARL)

Slenyto (RAD Neurim Pharmaceuticals EEC SARL)

Slenyto (Active substance: melatonin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2064 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4425/T/04

Europe -DG Health and Food Safety

7-3-2019

DaTSCAN (GE Healthcare B.V.)

DaTSCAN (GE Healthcare B.V.)

DaTSCAN (Active substance: Ioflupane (123I)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1908 of Thu, 07 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/266/T/57

Europe -DG Health and Food Safety

7-3-2019

Granpidam (Accord Healthcare S.L.U.)

Granpidam (Accord Healthcare S.L.U.)

Granpidam (Active substance: sildenafil) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1914 of Thu, 07 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4289/T/02

Europe -DG Health and Food Safety

7-3-2019

Pregabalin Accord (Accord Healthcare S.L.U.)

Pregabalin Accord (Accord Healthcare S.L.U.)

Pregabalin Accord (Active substance: pregabalin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1913 of Thu, 07 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4024/T/10

Europe -DG Health and Food Safety

7-3-2019

Aripiprazole Accord (Accord Healthcare S.L.U.)

Aripiprazole Accord (Accord Healthcare S.L.U.)

Aripiprazole Accord (Active substance: aripiprazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1915 of Thu, 07 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4021/T/13

Europe -DG Health and Food Safety

7-3-2019

Public meeting communique: Regulatory options for appropriate access and safety controls for alkyl nitrites

Public meeting communique: Regulatory options for appropriate access and safety controls for alkyl nitrites

Communique summarising outcomes of the alkyl nitrites public meetings in Sydney and Melbourne

Therapeutic Goods Administration - Australia

5-3-2019

Palonosetron Accord (Accord Healthcare S.L.U.)

Palonosetron Accord (Accord Healthcare S.L.U.)

Palonosetron Accord (Active substance: palonosetron) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1825 of Tue, 05 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4129/T/04

Europe -DG Health and Food Safety

5-3-2019

Docetaxel Accord (Accord Healthcare S.L.U.)

Docetaxel Accord (Accord Healthcare S.L.U.)

Docetaxel Accord (Active substance: Docetaxel) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1829 of Tue, 05 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2539/T/41

Europe -DG Health and Food Safety

5-3-2019

Tegsedi (Akcea Therapeutics Ireland Ltd)

Tegsedi (Akcea Therapeutics Ireland Ltd)

Tegsedi (Active substance: inotersen) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1826 of Tue, 05 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/004782/T/0003

Europe -DG Health and Food Safety

5-3-2019

Lacosamide Accord (Accord Healthcare S.L.U.)

Lacosamide Accord (Accord Healthcare S.L.U.)

Lacosamide Accord (Active substance: lacosamide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1831 of Tue, 05 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4443/T/02

Europe -DG Health and Food Safety

5-3-2019

Levetiracetam Accord (Accord Healthcare S.L.U.)

Levetiracetam Accord (Accord Healthcare S.L.U.)

Levetiracetam Accord (Active substance: levetiracetam) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1828 of Tue, 05 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2290/T/22

Europe -DG Health and Food Safety

5-3-2019

Lenalidomide Accord (Accord Healthcare S.L.U.)

Lenalidomide Accord (Accord Healthcare S.L.U.)

Lenalidomide Accord (Active substance: lenalidomide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1827 of Tue, 05 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4857/T/01

Europe -DG Health and Food Safety

4-3-2019

SME Assist Workshop: 'Meeting your obligations' (Sydney)

SME Assist Workshop: 'Meeting your obligations' (Sydney)

A free workshop aimed at beginners who are unfamiliar with therapeutic goods regulation

Therapeutic Goods Administration - Australia

1-3-2019

ACV meeting statement, Meeting 10, 3 October 2018

ACV meeting statement, Meeting 10, 3 October 2018

Advisory Committee on Vaccines meeting statement is now available

Therapeutic Goods Administration - Australia

27-2-2019

Bortezomib Accord (Accord Healthcare S.L.U.)

Bortezomib Accord (Accord Healthcare S.L.U.)

Bortezomib Accord (Active substance: bortezomib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1676 of Wed, 27 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/3984/T/17

Europe -DG Health and Food Safety

27-2-2019

Temozolomide Accord (Accord Healthcare S.L.U.)

Temozolomide Accord (Accord Healthcare S.L.U.)

Temozolomide Accord (Active substance: temozolomide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1681 of Wed, 27 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/001125/T/0045

Europe -DG Health and Food Safety

27-2-2019

Capecitabine Accord (Accord Healthcare S.L.U.)

Capecitabine Accord (Accord Healthcare S.L.U.)

Capecitabine Accord (Active substance: capecitabine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1682 of Wed, 27 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/002386/T/0030

Europe -DG Health and Food Safety

27-2-2019

Entecavir Accord (Accord Healthcare S.L.U.)

Entecavir Accord (Accord Healthcare S.L.U.)

Entecavir Accord (Active substance: entecavir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1684 of Wed, 27 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/004458/T/0004

Europe -DG Health and Food Safety

27-2-2019

Repaglinide Accord (Accord Healthcare S.L.U.)

Repaglinide Accord (Accord Healthcare S.L.U.)

Repaglinide Accord (Active substance: Repaglinide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1683 of Wed, 27 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/002318/T/0008

Europe -DG Health and Food Safety

27-2-2019

Hetlioz (Vanda Pharmaceuticals Germany GmbH)

Hetlioz (Vanda Pharmaceuticals Germany GmbH)

Hetlioz (Active substance: tasimelteon) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1668 of Wed, 27 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/3870/T/13

Europe -DG Health and Food Safety

25-2-2019

Vabomere (Menarini International Operations Luxembourg S.A.)

Vabomere (Menarini International Operations Luxembourg S.A.)

Vabomere (Active substance: meropenem/vaborbactam) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1591 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/004669/T/0001

Europe -DG Health and Food Safety

25-2-2019


Hearing with the Association of the European Self-Medication Industry during the September 2018 Working Party on Community Monographs and Community List meeting

Hearing with the Association of the European Self-Medication Industry during the September 2018 Working Party on Community Monographs and Community List meeting

Hearing with the Association of the European Self-Medication Industry during the September 2018 Working Party on Community Monographs and Community List meeting

Europe - EMA - European Medicines Agency

22-2-2019


Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Europe - EMA - European Medicines Agency

22-2-2019

Ibandronic acid Accord (Accord Healthcare S.L.U.)

Ibandronic acid Accord (Accord Healthcare S.L.U.)

Ibandronic acid Accord (Active substance: Ibandronic acid) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1582 of Fri, 22 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2638/T/16

Europe -DG Health and Food Safety

22-2-2019

Voriconazole Accord (Accord Healthcare S.L.U.)

Voriconazole Accord (Accord Healthcare S.L.U.)

Voriconazole Accord (Active substance: voriconazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1581 of Fri, 22 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2669/T/21

Europe -DG Health and Food Safety

20-2-2019

Pixuvri (CTI Life Sciences Deutschland GmbH)

Pixuvri (CTI Life Sciences Deutschland GmbH)

Pixuvri (Active substance: pixantrone) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1510 of Wed, 20 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/002055/T/0045

Europe -DG Health and Food Safety

18-2-2019

Fotivda (EUSA Pharma (Netherlands) B.V.)

Fotivda (EUSA Pharma (Netherlands) B.V.)

Fotivda (Active substance: tivozanib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1435 of Mon, 18 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4131/T/05

Europe -DG Health and Food Safety

18-2-2019

Imatinib Accord (Accord Healthcare S.L.U.)

Imatinib Accord (Accord Healthcare S.L.U.)

Imatinib Accord (Active substance: Imatinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1434 of Mon, 18 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2681/T/25

Europe -DG Health and Food Safety

18-2-2019

Pioglitazone Accord (Accord Healthcare S.L.U.)

Pioglitazone Accord (Accord Healthcare S.L.U.)

Pioglitazone Accord (Active substance: pioglitazone) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1432 of Mon, 18 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2277/T/16

Europe -DG Health and Food Safety

15-2-2019

Today, the @US_FDA announced an upcoming General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee Meeting that will take place on March 25-26. Learn more about the details and how to attend here:  https://go.usa.gov/xEUeu  #Medi

Today, the @US_FDA announced an upcoming General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee Meeting that will take place on March 25-26. Learn more about the details and how to attend here: https://go.usa.gov/xEUeu  #Medi

Today, the @US_FDA announced an upcoming General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee Meeting that will take place on March 25-26. Learn more about the details and how to attend here: https://go.usa.gov/xEUeu  #MedicalDevice #FDA

FDA - U.S. Food and Drug Administration

15-2-2019

Circadin (RAD Neurim Pharmaceuticals EEC SARL)

Circadin (RAD Neurim Pharmaceuticals EEC SARL)

Circadin (Active substance: Melatonin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1079 of Fri, 15 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/695/T/58

Europe -DG Health and Food Safety

15-2-2019

Caspofungin Accord (Accord Healthcare S.L.U.)

Caspofungin Accord (Accord Healthcare S.L.U.)

Caspofungin Accord (Active substance: caspofungin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1334 of Fri, 15 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4134/T/07

Europe -DG Health and Food Safety

15-2-2019


Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019

Europe - EMA - European Medicines Agency

14-2-2019

Yargesa (Piramal Critical Care B.V.)

Yargesa (Piramal Critical Care B.V.)

Yargesa (Active substance: miglustat) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1329 of Thu, 14 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/004016/T/0005

Europe -DG Health and Food Safety

11-2-2019

Lenvima (Eisai GmbH)

Lenvima (Eisai GmbH)

Lenvima (Active substance: lenvatinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1076 of Mon, 11 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/3727/T/24

Europe -DG Health and Food Safety

11-2-2019

Kisplyx (Eisai GmbH)

Kisplyx (Eisai GmbH)

Kisplyx (Active substance: lenvatinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1077 of Mon, 11 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4224/T/22

Europe -DG Health and Food Safety